Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution

Table 3 Univariate analysis of correlation of molecular markers with survival, disease progression, and response

Covariate	OS	TTP	OS from recurrence	Response at 3 months	Response at 6 months	Best response
Covariate	(HR) [95% CI]	(HR) [95% CI]	(HR) [95% CI]	(OR) [95% CI]	(OR) [95% CI]	(OR) [95% CI]
EGFR
Positive (n = 145)	1.05 (0.77-1.43)	0.82 (0.61-1.12)	1.02 (0.75-1.41)	0.64 (0.22-1.86)	0.64 (0.46-4.15)	1.06 (0.22-1.91)
Positive (n = 145)	P = .75	P = .21	P = .89	P = .41	P = .96	P = .43
Negative (n = 54)
Missing (n = 26)
p53
Positive (n = 105)	0.76 (0.55-1.05)	0.92 (0.66-1.27)	0.73 (0.52-1.03)	3.01 (1.04-8.7)	2.04 (0.68-6.1)	2.64 (0.99-7.1)
Positive (n = 105)	P = 0.10	P = .60	P = .071	P = .043	P = .21	P = .053
Negative (n = 97)
Missing (n = 23)
MGMT
Positive (n = 65)	0.97 (0.64-1.48)	0.90 (0.59-1.36)	1.42 (0.91-2.19)	1.36 (0.35-5.34)	1.02 (0.25-4.18)	1.78 (0.52-6.13)
Positive (n = 65)	P = 0.89	P = 0.61	P = .12	P = 0.66	P = .98	P = .36
Negative (n = 98)
Missing (n = 62)

Positive and negative expression are defined by ≥10% and <10% of cells, respectively, stained on immunohistochemical analysis. Abbreviations: CI confidence interval, HR hazard ratio, OR odds ratio, OS overall survival, TTP time to disease progression.

ISSN: 1471-2407